USFDA approves Tetraphase Pharma's antibiotic
The U. S. Food and Drug Administration approved Tetraphase Pharmaceuticals Inc's antibiotic for complicated intra-abdominal infections, providing a new option to combat the growing problem of treatment-resistant bacteria.
The approval allows the use of the drug, Xerava, in patients aged 18 and older.
The company said it expects to launch the drug in the United States in the fourth quarter.
(Reporting by Saumya Sibi Joseph and Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd